Elevated tissue levels of prostaglandin E 2 , produced by cyclooxygenase (COX), are an early event in colorectal cancer (CRC). Data suggest the efficacy of nonsteroidal anti-inflammatory drugs, such as cancer preventives, in the inhibition of COX activity; however, side effects of nonsteroidal anti-inflammatory pose unacceptable limitations. Ginger has been reported to have antiinflammatory activities with significant CRC preventive potential. We investigated whether consumption of 2.0 g ginger daily regulated the level of two key enzymes that control prostaglandin E 2 production, COX-1 and NAD + -dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Thirty participants at normal and 20 participants at increased risk for CRC were randomized and given 2.0 g/day ginger or placebo for 28 days. Flexible sigmoidoscopy was used to obtain colon biopsies at baseline and the end of the study. Tissue levels of COX-1 and 15-PGDH were assessed using western blotting. After ginger consumption, participants at increased risk for CRC had a significantly reduced colonic COX-1 protein level (23.8±41%) compared with the placebo group (18.9±52%; P = 0.03). Protein levels of 15-PGDH in the colon were unchanged. In participants who were at normal risk for CRC, neither protein levels of COX-1 nor 15-PGDH in the colon were altered by ginger consumption. Ginger significantly lowered COX-1 protein expression in participants at increased risk for CRC but not in those at normal risk for CRC. Ginger did not alter 15-PGDH protein expression in either increased or normal-risk participants. Further investigation, in larger studies with a longer ginger intervention, is needed to examine the ability of ginger to impact tissue levels of prostaglandin.
Introduction
Colorectal cancer (CRC) is the third most prevalent and second most deadly cancer in the USA (Jemal et al., 2010) . Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been shown to reduce CRC risk potentially through reduction of prostaglandin E 2 (PGE 2 ), an inflammatory metabolite of arachidonic acid that is strongly linked to colon tumor initiation and progression (Juarranz et al., 2002; Baron et al., 2003; Arber et al., 2006; Bertagnolli et al., 2006) . Cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) are thought to be the rate limiting enzymes for PGE 2 synthesis (Song et al., 2001) . However, in normal colonic tissue COX-2 expression is very low, generally not measurable, and basal level of PGE 2 is generated by COX-1 (Singer et al., 1998) . In addition to the production of PGE 2 , recent data have also suggested that PGE 2 catabolism through the NAD +dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme is downregulated in individuals with CRC (Backlund et al., 2005) . As such, targeting enzymes that synthesize (COX-1 and COX-2) and catabolize (15-PGDH) PGE 2 may be a more effective strategy for CRC prevention than simply inhibiting COX enzymes alone. Although aspirin and other NSAIDs inhibit COX enzymes, there is limited evidence that they affect 15-PGDH, and the side effects of NSAIDs in the cardiovascular and gastrointestinal system have raised concerns on their daily prescription to an otherwise healthy population (James and Hawkey, 2003; Solomon et al., 2005) . Therefore, alternative approaches such as utilizing natural nutritional components with low toxicity to affect COX/PGE 2 signaling represent potential areas of investigation for the prevention of CRC.
Ginger root (Zingiber officinale Roscoe, Zingiberaceae) is a traditional herbal dietary substance that has been used for gastrointestinal complaints for thousands of years and is one of the most commonly consumed herbs in the USA (Afzal et al., 2001; Cavaliere et al., 2010) . Ginger and ginger's most abundant nonvolatile pungent constituents, gingerols and shogaols, have demonstrated cancer inhibitory activity, such as growth suppression of colon and lung cancer cells (Sang et al., 2009) , tumor anti-antigenic potential (Brown et al., 2009) , and anti-inflammatory effects including inhibition of inducible COX-2 (Van Breemen et al., 2011) , inhibition of nuclear factor-kB (Kim et al., 2004; Aktan et al., 2006) , and inhibition of 5-lipoxygenase (Flynn et al., 1986; Kiuchi et al., 1992) . In-vivo studies using animal models of colorectal inflammation and carcinogenesis have confirmed the antioxidative, anti-inflammatory, and anticarcinogenic activities of ginger preparations (Yoshimi et al., 1992; Nalini, 2005, 2006; Ko and Leung, 2010) . In addition, a recent paper from our group reported that PGE 2 was reduced by ginger intake in normal looking colon tissue biopsies from a population with normal risk for CRC (Zick et al., 2011) . However, there are no data thus far examining the impact of dietary ginger on COX-1 or 15-PGDH concentrations in human colon mucosa.
The purpose of the current study was to assess the effect of ingesting 2.0 g of ginger root extract daily for 28 days on COX-1 and 15-PGDH concentrations in normal appearing human colonic mucosa. Colonic COX-1 and 15-PGDH were examined in people at both normal risk and increased risk for CRC.
Methods

Participants and drug
We conducted two blinded, parallel clinical trials in which participants were randomized into two equal groups either administered with ginger or a matching placebo (lactose) for 28 days. In the first study, which included participants at normal risk for CRC, we randomized 33 adult participants (of whom 30 completed the study; 16 placebo and 14 ginger). We defined normal risk participants according to the fulfillment of the following criteria: no history of familial CRC syndromes; no first-degree relatives diagnosed with colon cancer before the age of 60; no adenomas greater than 1 cm in size or containing carcinomas in situ; and no history of CRC. The second study focused on people at high risk for CRC among whom 21 were randomized and 20 completed the trial (10 ginger and 10 placebo). High risk for CRC was defined based on fulfillment of the following criteria: a first-degree relative diagnosed with CRC before the age of 60; prior CRC, which should have been fully excised and either Duke's A or B; or a history of a previous adenoma.
Other eligibility criteria for the normal-risk participants have been previously published (Zick et al., 2011) . However, with the exception of the high-risk and lowrisk definitions, eligibility criteria were identical in the two studies. In brief, in addition to the low-risk or highrisk determination, participants needed to be 18 years or older and in general good health. Participants should also not have taken any corticosteroid, NSAID, or aspirin during or within 14 days of starting the study nor should they have eaten any ginger supplements or foods that contain ginger. For both trials, study procedures were administered at the University of Michigan Clinical Research Unit after the participants gave their written informed consent. The study was approved by the Institutional Review Board of the University of Michigan.
Participants were asked to take eight 250 mg capsules of ginger extract daily for a total dosage of 2.0 g/day. The ginger product used in both studies was manufactured by Pure Encapsulations (Sudbury, Massachusetts, USA). Details of formulation, quality control, and drug dispersal for the ginger extract has been described previously (Zick et al., 2011) .
Randomization, allocation, and blinding
In both studies, participants were randomized equally to one of two groups: placebo or ginger extract (2.0 g). The randomization code was computer-generated by the study biostatistician and kept by the University of Michigan's Investigational Drug Service. The University of Michigan's Investigational Drug Service assigned the next available randomization number when informed about the next eligible participant. Participants and study team members who worked with study data, assessed outcomes, or administered questionnaires were unaware of the treatment assignment.
Flexible sigmoidoscopy and tissue process
Flexible sigmoidoscopies were performed at baseline before drug treatment started and at day 28, as soon as possible to 24 h after the participants ingested the final study drug. The participants were not prepared for the procedure with any enemas; however, they were asked to evacuate their rectum within 12 h of sigmoidoscopy. Four tissue samples were taken using the biopsy forceps and each biopsy specimen was taken B2-5 cm from other biopsy sites in the distal sigmoid colonic mucosa.
Biopsy samples were frozen in liquid nitrogen exactly 50 s after closing of the biopsy forceps, and they were stored at -701C until analysis. Two frozen colonic biopsy specimens of B5 mg each from the same participant and time point were combined and pulverized to a fine powder using a liquid-nitrogen-cooled mortar. Samples were then transferred to sealed microcentrifuge tubes, mixed with three volumes of ice-cold PBS buffer containing 0.1% butylated hydroxytoluene and 1 mmol/l EDTA, and then homogenized using an Ultrasonic Processor (Misonix, Farmingdale, New Jersey, USA) at 01C for 3 min. The protein concentration in the homogenate was determined by the Bradford protein assay (Bio-Rad, Hercules, California, USA).
Western blot analysis
Proteins (30 mg) were separated by SDS-PAGE using a 10% resolving polyacrylamide gel and then transferred onto a polyvinylidene difluoride membrane. The membrane was incubated with COX-1 antibody (Invitrogen, Camarillo, California, USA), 15-PGDH antibody (Santa Cruz Biology Inc., Santa Cruz, California, USA), and actin antibody (Abcam, San Francisco, California, USA). The images were quantified using the MCID software (InterFocus Imaging Ltd, Cambridge, UK). Participants were randomly selected onto the same gel, and the absolute values of the protein expression were quantified using the darkness of the COX-1 or 15-PGDH bands divided by the darkness of actin bands.
Statistics
Statistical analyses were carried out using PASW Statistics 18 (Somers, New York, USA). Protein levels of COX-1 and 15-PGDH were normalized to that of actin. For each participant, the percentage difference in COX-1 and 15-PGDH protein levels between baseline and day 28 within groups was calculated as 100 Â (post-pre)/pre. A P-value of up to 0.05 was considered statistically significant. We did not control for batch variability as analysis controlling for gel-to-gel variation did not change results quantitatively (data not shown). We performed t-tests to compare the difference in protein expression of COX-1 and 15-PGDH at baseline between the two dietary groups and found no statistical difference across treatment groups. Because the studies were powered for the original endpoint of PGE 2 , we decided to conduct a post-hoc power analysis to determine our ability to detect significant changes in COX-1 and PGDH-15 enzymes. On the basis of our estimates of mean differences and associated variability for COX-1 in the highrisk group, a two-sample t-test with Satterthwaite's approximation required 26 participants per group to detect the observed effect size with 80% power and a 5% level of significance. The observed effect size for 15-PGDH was substantially smaller. A post-hoc power calculation similar to that for COX-1 estimated a requirement of 148 participants per group.
Results
Participants
We screened 50 individuals for the normal-risk study from January 2007 to June 2008 and 42 people for the high-risk study from June 2009 to January 2010. For the normal-risk study, we randomized 33 participants (17 to placebo and 16 to ginger) after excluding 17 for either identified chronic health issues (n = 14) or lack of further interest in the study (n = 3). Of the 33 participants, one participant from the placebo group (because of a GI complaint) and two from the ginger group (one because of a headache and one lost to follow-up) did not complete the study.
From among the participants who were at increased risk for CRC, we excluded 21, primarily because 13 of them were found not to be at an increased risk for CRC, two of them had secondary cancers, two had lost interest in participating in the study, one had a myocardial infarction between screening and baseline, one had administered a supplement that would interfere with assessments of the study endpoints, and one was suspected of having Lynch syndrome. Of the 21 participants randomized (10 to placebo and 11 to ginger), one participant in the ginger arm was later withdrawn after discovering that he was at normal risk for CRC, leaving 10 participants in the ginger and 10 in the placebo arm who completed the increased-risk trial.
For both normal-risk and increased-risk participants, there was no significant difference at baseline between the groups for any demographic or clinical characteristics (Table 1 ). The participants from the two trials were similar to each other with the exception of age. Participants in the high-risk study were on average older, with a mean age of 51±12.9 (SD), whereas those in the normal-risk study had a mean age of 33.5±11.5 (SD).
Cyclooxygenase-1
We found that there was no significant difference (P = 0.06) in COX-1 protein expression between the ginger and placebo groups for the normal-risk participants ( Table 2 and Fig. 1 ). However, our results did indicate that in participants at increased risk for CRC, the protein expression of COX-1 in the colon biopsies was significantly inhibited (P = 0.03) on consumption of ginger root extract for 28 days compared with that in the placebo group (Table 2 and Fig. 2) . In the increased-risk participants, colonic COX-1 protein expression was decreased by 23.8±42% from preintervention to postintervention in the ginger arm and increased by 18.9±52% in the placebo arm.
15-Hydroxyprostaglandin
Our results did not indicate any significant difference in changes of colonic 15-PGDH protein levels between the ginger and placebo groups after 28 days of ginger supplementation ( Table 2 and Figs 1 and 2) . This was true for both participants at normal and at increased risk for CRC (P = 0.83 and 0.49, respectively).
Discussion
We found that after short-term ginger root extract intervention, basal COX-1 protein expression in normal appearing colonic mucosa was significantly decreased (P = 0.03; 23.8%) in the ginger group compared with an 18.9% increase observed in the placebo group in participants at increased risk for CRC. In contrast, in participants at normal risk for CRC, we saw no significant difference (P = 0.06) between groups, with the ginger group showing a very slight decrease of 3.7% and the placebo group showing an increase of 16.0%. There was also no significant change in basal 15-PGDH protein expression in participants at normal (P = 0.83) or increased risk (P = 0.49) for CRC, regardless of whether they received ginger or placebo.
Our previous work on the same group of participants at normal risk for CRC showed that a 2.0 g dose of ginger root extract administered for 28 days was able to significantly reduce PGE 2 concentrations in normal appearing colonic mucosa compared with placebo (Yoshimi et al., 1992) .
Similar to our findings, previous evidence determined that ginger extract or key ginger constituents reduced COX-2 mRNA expression activity in vitro, which in turn resulted in a decrease in PGE 2 production (Tjendraputra et al., 2001; Jolad et al., 2005; Van Breemen et al., 2011) . Although COX-2 was reported to be responsible for the antiinflammatory effect of ginger by several studies, the expression of COX-2 was so low in normal colon tissue that other mechanisms could be involved in controlling basal PGE 2 levels. Thus, it appears that COX-1 is the most likely candidate for the synthesis of basal levels of PGE 2 in healthy colon mucosa. In addition, COX-1 inhibition is a probable target of the ginger root extract for reducing PGE 2 concentrations in healthy appearing colon mucosa (Zick et al., 2011) . As a consequence, we have hypothesized that the reduction in colonic PGE 2 in our ginger trial could be due to the decrease in COX-1 protein expression reported. However, we were unable to interrogate PGE synthase, an enzyme that is responsible for the final stage of synthesis of PGE 2 . As such, decreased PGE 2 concentrations in healthy colon tissue could be because of the inhibition of either or both COX-1 and PGE synthase by ginger root extract. In contrast, as COX-1 is a constitutively expressed protein with the function of producing eicosanoids that can be proinflammatory and anti-inflammatory, one would not expect a substantial change in healthy people. Therefore, a mild reduction in COX-1 levels would potentially decrease the production of PGE 2 , and, in the meantime, maintain the basal levels of eicosanoids that are necessary for healthy function of colonic mucosa.
This study had several limitations. These include a relatively small sample size, which was powered on the basis of our primary endpoint, PGE 2 ; a short intervention period; and a fairly large amount of variability for 15-PGDH. Our samples sizes were relatively small and intervention period short as this study was intended to be a pilot for a larger human trial. Thus, it is possible that extended ginger consumption and more participants might provide additional power to detect the effects of dietary ginger root intake on the prostaglandin pathway. In addition, we analyzed factors (data not shown) that may have potentially interfered with the study outcome, such as age, sex, BMI, and other characteristics of the participants. However, no additional factors that were associated with the changes in COX-1 and 15-PGDH protein expression in either normal-risk or high CRC risk participants were identified. It is still possible that elements that were not taken into consideration in our studies may be responsible for changes in enzyme protein expression.
As indicated, there were considerable variations in changes of 15-PGDH protein expression in both groups. This is in contrast to COX-1 protein expression in which little variability was observed. The large variability in 15-PGDH protein expression implies that responders and nonresponders were included in a relatively small group of participants. Despite this, whether ginger is capable of altering 15-PGDH protein expression in a subset of individuals requires further research in a larger study sample.
In addition, it is important to note that the western blotting assay for the two studies was run separately and at different times. As such, we can only compare the data within the study and not across the two studies. Despite not being able to compare the protein levels across the two studies, we are able to compare the post/pre ratio of COX-1 or 15-PGDH protein expression between the placebo and ginger groups within studies as both post and pre samples from one individual were included on one gel.
Conclusion
We conducted two human trials using placebo/ginger root extract supplementation for 28 days. Our results indicate that ginger extract was able to reduced basal COX-1 protein expression in colon biopsies from participants with an increased risk for CRC, indicating that ginger may potentially decrease human colonic PGE 2 synthesis from arachidonic acid, especially in individuals with high risk for CRC. Whether ginger can be used as a cancer preventive agent for CRC in a healthy population still requires further investigation with bigger groups of participants and longer intervention periods.
